Alibaba and its US digital payment processor have agreed to pay 600 million dollars to resolve a federal investigation into whether they failed to prevent the sale and importation of illegal pharmaceuticals and controlled substances, the Justice Department said on Wednesday. Alibaba entered into a non-prosecution agreement to end a probe of alleged violations of […]

This story continues at The Next Web